argatroban / Generic mfg. - LARVOL DELTA

Argatroban mitigates Klebsiella pneumoniae liver injury by attenuating ZBP1-dependent PANoptosis. (PubMed, Int Immunopharmacol) - "Argatroban protects against KPLA-associated liver injury by inhibiting a TLR4 endocytosis-TBK1/IRF3-STAT1-ZBP1 axis and suppressing ZBP1-dependent PANoptosis, identifying PANoptosis as a potential therapeutic target in severe K. pneumoniae infection."

Journal • Hepatology • Infectious Disease • Inflammation • Liver Failure • Pneumonia • CASP3 • CASP8 • IGF2BP1 • STAT1 • TLR4 • ZBP1

Impact of non-amyloid cerebral small vessel disease on the efficacy and safety of argatroban in acute ischemic stroke: a retrospective cohort study. (PubMed, Front Neurol) - "In patients with AIS after exclusion of cerebral amyloid angiopathy, argatroban improves early neurological function but does not improve functional outcome at 90 days. Severe white matter hyperintensities may be potential effect modifiers, generating hypotheses for imaging-based treatment stratification that warrant prospective validation."

Journal • Retrospective data • Cardiovascular • Cerebral Hemorrhage • Ischemic stroke

Comparison of clinical efficacy between argatroban and tirofiban in patients with atherosclerotic cerebral infarction complicated by early neurological deterioration. (PubMed, Front Pharmacol) - "No statistically significant differences were detected in overall efficacy or safety outcomes between argatroban and tirofiban in patients with END after atherosclerosis-related ischemic stroke. Subgroup findings suggest that treatment effects may vary according to stroke subtype, highlighting the need for further prospective studies to explore mechanism-based, individualized antithrombotic strategies."

Journal • Atherosclerosis • Cardiovascular • CNS Disorders • Ischemic stroke

Massive aortic thrombus in a hypercoagulable patient with heparin induced thrombocytopenia: a case report. (PubMed, J Surg Case Rep) - "Following stabilization of acute HIT with argatroban, surgical thrombectomy of the large aortic thrombus and endarterectomy of a penetrating aortic ulcer was successfully performed using bivalirudin anticoagulation for cardiopulmonary bypass without complication. Postoperatively the patient was maintained on argatroban followed by transition to outpatient warfarin without new thromboembolic or bleeding complications."

Journal • Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

Balancing Hemorrhage and Thrombosis: FEIBA Use in a Polytrauma Patient with Acute HIT (ASA 2026) - "Management required strict heparin avoidance, temporary interruption and reversal of argatroban and apixaban, invasive hemodynamic monitoring, vasopressor support, blood transfusion, and urgent administration of FEIBA as a heparin-free prohemostatic agent to reverse apixaban. Following hemostasis, antithrombotic therapy was carefully reinitiated to minimize the risk of stent thrombosis. This case highlights the anesthetic challenge of balancing catastrophic hemorrhage and extreme thrombotic risk in acute HIT, while emphasizing FEIBA (Anti-inhibitor coagulant complex) as an underrecognized reversal option."

Clinical • Cardiovascular • Hematological Disorders • Thrombosis

Possible atypical heparin-induced thrombocytopenia presenting with splenic infarction despite preserved platelet counts after cardiac surgery - a case report. (PubMed, Front Med (Lausanne)) - "Anticoagulation was changed to argatroban, followed by apixaban. Importantly, although an initial perioperative platelet decline of 59% was observed consistent with cardiopulmonary bypass-related consumption, platelet counts had recovered to within the normal range at the time of diagnosis, and no classical secondary platelet fall was observed. In summary, we report a case of possible HIT in which platelet count-based risk stratification may not have fully captured an atypical presentation in this selected clinical setting."

Journal • Cardiovascular • Critical care • Hematological Disorders • Ischemic stroke • Thrombocytopenia

Ultra-Low Dose Argatroban in Heparin-Induced Thrombocytopenia with Thrombocytopenia and Hypofibrinogenemia: A Case Report. (PubMed, TH Open) - "By day 12 postdiagnosis, platelet count recovered to 176 × 10 9 /L, permitting successful definitive orthopedic surgery on day 13 without bleeding complications. This case illustrates that in HIT with life-threatening thrombosis and extreme bleeding risk, an individualized "start low, go slow" argatroban strategy with delayed initiation achieves effective anticoagulation while minimizing hemorrhagic risk."

Journal • Cardiovascular • Hematological Disorders • Orthopedics • Pulmonary Embolism • Respiratory Diseases • Thrombocytopenia

Transcatheter Edge-to-Edge Repair Under Argatroban in IABP-Supported Acute Mitral Regurgitation With Suspected Heparin-Induced Thrombocytopenia. (PubMed, JACC Case Rep) - "M-TEER under argatroban may serve as a rescue strategy for critically ill patients with acute severe MR and suspected HIT when surgical management is not feasible."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Thrombocytopenia

Heparin-induced thrombocytopenia with irreversible microvascular gangrene in a patient receiving venovenous-ECMO for hypervirulent Klebsiella pneumoniae sepsis. (PubMed, Intensive Crit Care Nurs) - No abstract available

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Pneumonia • Septic Shock • Thrombocytopenia • Thrombosis

Clinical efficacy and safety of tenecteplase combined with argatroban for acute ischemic stroke: A single-center retrospective cohort study. (PubMed, Medicine (Baltimore)) - "We conducted a single-center retrospective cohort study of consecutive adults with acute ischemic stroke admitted between January 2023 and December 2024, comparing a control regimen of standard-dose recombinant tissue plasminogen activator (alteplase 0.9 mg/kg, maximum 90 mg) with an observation regimen of low-dose recombinant tissue plasminogen activator (0.6 mg/kg, maximum 60 mg) plus argatroban initiated after thrombolysis in clinically stable patients. Symptomatic intracranial hemorrhage and other adverse events were uncommon, without significant between-group differences. These real-world findings should be considered hypothesis-generating and require prospective randomized validation."

Journal • Retrospective data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Thrombosis

TENDYNE mitral valve implantation complicated by heparin-induced thrombocytopenia in a patient with NSCLC: a case report. (PubMed, Eur Heart J Case Rep) - "The early postoperative course was complicated by heparin-induced thrombocytopenia (HIT) type II, resulting in progressive thrombosis of the left atrium and prosthetic valve despite therapeutic anticoagulation with argatroban...After multidisciplinary perioperative management, including tailored anticoagulation strategies, the patient recovered and was discharged in stable condition. This case highlights the interplay between TMVR-associated thrombogenicity, HIT-driven hypercoagulability, and the complexity of treatment sequencing in cardio-oncology patients, emphasizing the importance of individualized, interdisciplinary decision-making."

Journal • Cardiovascular • Hematological Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia • Thrombosis

Room-Temperature Stability of Argatroban, Danaparoid, and Fondaparinux in Plasma: A Multicenter Study. (PubMed, Thromb Haemost) - "no need."

Clinical • Journal

Evaluation of argatroban to warfarin transition process in heparin-induced thrombocytopenia. (PubMed, J Thromb Thrombolysis) - "The process for transitioning HIT patients from argatroban to warfarin is complex. The low rate of compliance and transition success highlights the challenging nature of this transition."

Journal • Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

Investigating pyroptosis inhibition to rescue severe Influenza A Virus infection (ISTH 2026) - "Results Protein network and pathway analyses identified significantly upregulated protein clusters associated with severe infection during peak inflammation which were downregulated by Argatroban pretreatment...Inhibition of GSDMD using Disulfiram after symptom appearance at days 3 and 4 post- severe IAV infection mitigated weight loss and lung damage as measured by MPO and wet-to-dry ratios...Further investigation into mechanisms underlying mitigation of severe IAV infection by target proteins and their connection to thromboinflammation is underway to complement these findings. DOI*10.1016/j.rpth.2026.106351"

Infectious Disease • Inflammation • Influenza • Pneumonia • Respiratory Diseases • MPO

Stability durations of argatroban, danaparoid sodium, and fondaparinux sodium assays in plasma samples stored at room temperature. (ISTH 2026) - "The limitations of this study may include the sample size, though it is sufficient (>30 samples/molecule) given the frequency of these prescriptions in our laboratories, as well as the use of frozen samples. However, since freezing may represent a more challenging condition than fresh plasma measurements, our results can be extrapolated to routine room-temperature storage conditions Table or Figure Upload (1) Page 2 DOI*10.1016/j.rpth.2026.105400"

Adsorption of argatroban by activated charcoal-based compounds: Improvement of biological follow‑up in patients with heparin‑induced thrombocytopenia (ISTH 2026) - "Argatroban ‑ related plasmatic interferences expressed as the difference (Δ) between values before and after argatroban removal using activated charcoal-based compounds (n=31) Page 2 Table or Figure Upload (2) Figure 1. Argatroban ‑ related plasmatic interference on INR (n=489) DOI*10.1016/j.rpth.2026.105379"

Clinical • Hematological Disorders • Renal Disease • Thrombocytopenia

Recurrent Thrombosis on Therapeutic Apixaban While on Pembrolizumab Therapy in Pediatric Cancer: A Case Report. (ISTH 2026) - "He completed 12 cycles of carboplatin/paclitaxel through a right femoral mediport and radiation therapy (RT), achieving complete remission (CR)...Thrombocytopenia on day 3 of anticoagulation prompted transition to argatroban for suspected heparin-induced thrombocytopenia (HIT)...DOACs, due to single-target inhibition, are inferior to heparin and warfarin in highly thrombogenic conditions as evidenced by their failure in antiphospholipid syndrome and mechanical heart valves. As pediatric immunotherapy use expands, careful risk stratification and tailored thromboprophylaxis in pediatrics are warranted. DOI*10.1016/j.rpth.2026.105081"

Case report • Clinical • Genetic Disorders • Nasopharyngeal Carcinoma • Oncology • Pediatrics • Respiratory Diseases • Thrombocytopenia • Thrombosis • Venous Thromboembolism

Implementation of a structured diagnostic pathway and a multidisciplinary management for heparin-induced thrombocytopenia: experience from a high-volume CPB cardiac surgery and ECMO center (ISTH 2026) - "After switching (9 argatroban; 2 danaparoid; 3 DOACs), median time to >50% platelet recovery from nadir was 3 days [2.75; 4.25]; median time to thrombocytopenia resolution was 7 days [3; 16] (3.5 days excluding persistent cases). Page 2 Table or Figure Upload (2) Table 1. DOI*10.1016/j.rpth.2026.104413"

Surgery • Cardiovascular • Hematological Disorders • Thrombocytopenia

Clinical and biological description of heparin-induced thrombocytopenia in transplant recipients: a single-center retrospective study (ISTH 2026) - "Sixteen (64%) patients were initially treated with argatroban and 5 (20%) with danaparoid. Conclusions These results highlight the importance of functional tests to confirm the diagnosis of HIT in transplant recipients, particularly cardiac transplant recipients, and demonstrate the difficulty of managing these especially frail patients. DOI*10.1016/j.rpth.2026.104406"

Retrospective data • Cardiovascular • Hematological Disorders • Solid Organ Transplantation • Thrombocytopenia • Thrombosis • Transplantation

Evaluation of activated charcoal to neutralize argatroban induced interferences on routine coagulation tests (ISTH 2026) - "This is particularly useful during the transition from argatroban to VKA, where argatroban artificially increases the INR. Table or Figure Upload (1) Page 2 Table or Figure Upload (2) Page 3 DOI*10.1016/j.rpth.2026.104441"

Hematological Disorders • Thrombocytopenia

Fondaparinux versus Argatroban for the Management of Heparin-Induced Thrombocytopenia in Hemodynamically Stable and Unstable Patients: A Propensity Score–Matched Cohort Study (ISTH 2026) - "The higher ICU mortality observed with argatroban, amid residual renal imbalance, warrants confirmation in larger, prospective studies. DOI*10.1016/j.rpth.2026.104439"

Clinical • Acute Kidney Injury • Cardiovascular • Hematological Disorders • Nephrology • Renal Disease • Thrombocytopenia • Thrombosis

Case Report: Heparin resistance as the harbinger of heparin-induced thrombocytopenia in acute pulmonary embolism. (PubMed, Front Med (Lausanne)) - "After platelet count recovery (to >150 × 109/L), argatroban was discontinued and anticoagulation was switched to oral rivaroxaban. This case underscores that unexplained heparin resistance with thrombotic progression, even preceding significant thrombocytopenia, a recognized harbinger of HIT-associated thrombosis, is a critical indicator of HIT. Immediate diagnostic evaluation and switch to non-heparin anticoagulants are imperative to avert life-threatening complications."

Journal • Cardiovascular • Hematological Disorders • Pulmonary Embolism • Respiratory Diseases • Thrombocytopenia

Case Report: HIT-related valve thrombosis in an LVAD patient. (PubMed, Front Cardiovasc Med) - "The anticoagulation regimen was promptly switched to the direct thrombin inhibitor argatroban, after which the patient's condition stabilized. This case highlights the diagnostic and therapeutic challenges of managing HIT-related thrombosis in the setting of continuous-flow LVAD support and aims to review the underlying pathophysiology and optimal anticoagulation strategy."

Journal • Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

Efficacy and safety of treatment strategies for early neurological deterioration after acute ischemic stroke: a network meta-analysis of randomized controlled trials. (PubMed, BMC Neurol) - "Indobufen was associated with lower mean 90-day mRS and NIHSS scores, whereas tirofiban added to standard antiplatelet therapy increased the proportion of patients achieving a favorable functional outcome defined as mRS 0-2. Neither tirofiban nor argatroban significantly increased the proportion achieving an excellent functional outcome defined as mRS 0-1. These findings should be interpreted cautiously because of the limited number and size of the included trials."

Journal • Retrospective data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Urgent Transcatheter Aortic Valve Replacement in Acute Heparin-Induced Thrombocytopenia Using Argatroban and Crossover Technique. (PubMed, Can J Cardiol) - "Argatroban was used as the periprocedural anticoagulant, and a crossover technique enabled complete hemostasis despite a critically low platelet count. This case demonstrates that a fully percutaneous TAVR strategy using argatroban can be safely performed during acute HIT and provides a practical approach for structural heart interventions in patients at high bleeding risk."

Journal • Anesthesia • Gastroenterology • Hematological Disorders • Thrombocytopenia